101 related articles for article (PubMed ID: 17107924)
1. Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia.
Burger JA; Schmitt-Gräff A; Bürkle A; Seiler L; Finke J
Leuk Lymphoma; 2006 Nov; 47(11):2427-30. PubMed ID: 17107924
[No Abstract] [Full Text] [Related]
2. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
[No Abstract] [Full Text] [Related]
3. Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes.
Oka S; Muroi K; Mori M; Matsuyama T; Fujiwara S; Oh I; Sato K; Kikuchi S; Ueda M; Toshima M; Suzuki T; Ozaki K; Nagai T; Ozawa K
Leuk Lymphoma; 2009 Feb; 50(2):290-3. PubMed ID: 19197727
[No Abstract] [Full Text] [Related]
4. How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
Ross DM; Hughes TP
Leuk Lymphoma; 2008 Jul; 49(7):1230-1. PubMed ID: 18604711
[No Abstract] [Full Text] [Related]
5. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Atallah E; Talpaz M; O'brien S; Rios MB; Guo JQ; Arlinghaus R; Fernandes-Reese S; Kantarjian H
Cancer; 2002 Jun; 94(11):2996-9. PubMed ID: 12115389
[TBL] [Abstract][Full Text] [Related]
7. Unusual extramedullary relapse of CML.
Smaradottir A; Kapur D; Bilgrami S
Ann Oncol; 2004 Aug; 15(8):1296-7. PubMed ID: 15277274
[No Abstract] [Full Text] [Related]
8. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
[No Abstract] [Full Text] [Related]
9. Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.
Yamazaki R; Aisa Y; Mori T; Iketani O; Ikeda Y; Okamoto S
Leuk Lymphoma; 2009 Apr; 50(4):670-2. PubMed ID: 19373671
[No Abstract] [Full Text] [Related]
10. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
[No Abstract] [Full Text] [Related]
11. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
12. Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy.
Saulnier PJ; Dalbiès F; Berthou C; Guilhot F; Bourmeyster N; Chomel JC; Thuran A
Leuk Lymphoma; 2008 Apr; 49(4):815-6. PubMed ID: 18398751
[No Abstract] [Full Text] [Related]
13. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
14. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
16. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
Mattison R; Larson RA
Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
[No Abstract] [Full Text] [Related]
17. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
18. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
19. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Brümmendorf TH; Ersöz I; Hartmann U; Bartolovic K; Balabanov S; Wahl A; Paschka P; Kreil S; Lahaye T; Berger U; Gschaidmeier H; Bokemeyer C; Hehlmann R; Dietz K; Lansdorp PM; Kanz L; Hochhaus A
Blood; 2003 Jan; 101(1):375-6. PubMed ID: 12485943
[No Abstract] [Full Text] [Related]
20. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
Vora A; Bhutani M; Sharma A; Raina V
Ann Oncol; 2002 Nov; 13(11):1833-4. PubMed ID: 12419759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
